Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
UK-Förderung (69.170 £): Commercial Opportunities for Pulmonary Diagnosis (COPD) Ukri01.04.2018 Forschung und Innovation im Vereinigten Königreich, Großbritannien
Auf einen Blick
Text
Commercial Opportunities for Pulmonary Diagnosis (COPD)
| Zusammenfassung | "Innovate UK has awarded a feasibility research grant to Cambridge Respiratory Innovations Limited, of Swavesey, Cambridgeshire. Currently a clinician needs to use a range of medical devices, from peak-flow meters through spirometers and pulse oximeters to scans and x-rays, to diagnose a respiratory condition. The most commonly used devices to diagnose asthma, COPD and other chronic respiratory diseases are spirometers and peak-flow meters. Both devices are difficult for patients to use, rely on forced expiratory manoeuvres, are technique dependent and measure a respiratory proxy. Adults in respiratory distress and children cannot use these devices. Cambridge Respiratory Innovations Limited (CRiL) has developed an innovative epitaxially-grown III-V LED-based CO2 sensor which is faster, more accurate and more consistent than any existing incandescent or florescent CO2 sensor. It is not affected by condensation in the breath and is a fraction of the cost. CRiL has developed it specifically to measure the CO2 waveform shape in normal tidal breathing to use in low-cost personal respiratory monitors. Tidal breathing CO2 (TBCO2) waveform shape analysis is an established but under-used biomarker for respiratory conditions. Whilst medical devices that measure exhaled CO2 (capnometers) are commonplace in the operating theatre, devices that measure tidal breathing CO2 are not used in any form of respiratory diagnosis at the moment. This project focuses on the research, development and adoption issues that the N-Tidal diagnostic concept will need to address and the likelihood of success in commercialisation in the primary and secondary care medical communities. The objectives of this project are to clarify the value proposition of the concept to help healthcare providers and other customers to understand the attractiveness of the N-Tidal diagnostic device. This includes determining: * patient and end user needs * the required changes to patient pathways * commissioning and procurement options * health economics * adoption drivers The main areas of focus of the research will be the users' needs, the value proposition, the health economics and the clinical evidence required for successful commercialisation. The primary output from this study will be a validated and fully-costed development plan. This commercialisation feasibility study will identify whether there are any commercial, economic or evidence impediments which hinder the adoption of the N-Tidal respiratory diagnostic device based on tidal breathing CO2 measurement." |
| Kategorie | Feasibility Studies |
| Referenz | 133437 |
| Status | Closed |
| Laufzeit von | 01.04.2018 |
| Laufzeit bis | 31.12.2018 |
| Fördersumme | 69.170,00 £ |
| Quelle | https://gtr.ukri.org/projects?ref=133437 |
Beteiligte Organisationen
| Cambridge Respiratory Innovations Limited |
69.170,00 £ |
Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der aktuelle Stand wird auf folgender Seite wiedergegeben: Tidalsense Ltd., Cambridge, Großbritannien.
Die Visualisierungen zu "Cambridge Respiratory Innovations Ltd. - UK-Förderung (69.170 £): Commercial Opportunities for Pulmonary Diagnosis (COPD)"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
